Successful treatment of refractory interstitial lung disease with cyclophosphamide and pirfenidone in a new onset of juvenile SLE: a case report

环磷酰胺和吡非尼酮成功治疗新发幼年系统性红斑狼疮合并难治性间质性肺病:病例报告

阅读:1

Abstract

INTRODUCTION AND IMPORTANCE: Systemic lupus erythematosus (SLE) is a systemic immune disease, presented with a broad spectrum of clinical manifestations. The occurrence of interstitial lung disease (ILD) as the initial manifestation of SLE is very rare. CASE PRESENTATION: The authors present the case of a 6-year-old girl who presented with symptoms of fatigue, fever, oral ulcers, and dry cough with difficulty breathing. On physical examination, the patient had fever and oral ulcers, in addition of acute phase reactant analysis, positive ANA, and double-stranded DNA. Chest computed tomography images showed nonspecific interstitial pneumonia + organizing pneumonia pattern, leading to the diagnosis of onset of SLE with ILD. The patient was treated with steroids and azathioprine for 1 year, and the radiological and immunological resolution was noted. However, the patient continued to cough, have difficulty breathing, and was readmitted to the hospital due to SLE recurrence after 1 year of follow-up. Despite continued corticosteroid therapy and monthly administration of steroids and cyclophosphamide for 6 months, the patient's respiratory symptoms and chest radiography results did not improve significantly. The patient was then prescribed a daily regimen of cyclophosphamide and pirfenidone, which was found to be effective in reducing the steroid dose and achieving remission after 1 year of follow-up. CLINICAL DISCUSSION: Treatment of connective tissue disease-associated ILD is difficult due to a lack of treatment data. CONCLUSION: This case provided evidence of the efficacy of combination therapy of pirfenidone and cyclophosphamide for refractory connective tissue disease-associated ILD in young children.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。